Cargando…
The therapeutic potential of genome editing for β-thalassemia
The rapid advances in the field of genome editing using targeted endonucleases have called considerable attention to the potential of this technology for human gene therapy. Targeted correction of disease-causing mutations could ensure lifelong, tissue-specific expression of the relevant gene, there...
Autores principales: | Glaser, Astrid, McColl, Bradley, Vadolas, Jim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
F1000Research
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4753996/ https://www.ncbi.nlm.nih.gov/pubmed/26918126 http://dx.doi.org/10.12688/f1000research.7087.1 |
Ejemplares similares
-
GFP to BFP Conversion: A Versatile Assay for the Quantification of CRISPR/Cas9-mediated Genome Editing
por: Glaser, Astrid, et al.
Publicado: (2016) -
Animal models of β-hemoglobinopathies: utility and limitations
por: McColl, Bradley, et al.
Publicado: (2016) -
Coordinated β-globin expression and α2-globin reduction in a multiplex lentiviral gene therapy vector for β-thalassemia
por: Nualkaew, Tiwaporn, et al.
Publicado: (2021) -
A Cas9 Variant for Efficient Generation of Indel-Free Knockin or Gene-Corrected Human Pluripotent Stem Cells
por: Howden, Sara E., et al.
Publicado: (2016) -
Epigenetic Insights and Potential Modifiers as Therapeutic Targets in β–Thalassemia
por: Zakaria, Nur Atikah, et al.
Publicado: (2021)